Do you want to read an article? Please log in or register.
Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results
Swiss Med Wkly.
Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C
doi: 10.4414/smw.2018.14593.
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/
Pulmonary Fibrosis
Effects of Lumacaftor/Ivacaftor Therapy on CFTR Function in Phe508del Homozygous Patients with Cystic Fibrosis
Am J Respir Crit Care Med.
Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B
doi: 10.1164/
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
Pulmonary Fibrosis
Initial clinical evaluation of stationary digital chest tomosynthesis in adult patients with cystic fibrosis
Eur Radiol.
Gunnell ET, Franceschi DK, Inscoe CR, Hartman A, Goralski JL, Ceppe A, Handly B, Sams C, Fordham LA, Lu J, Zhou O, Lee YZ
doi: 10.1007/s00330-018-5703-9.
Pulmonary FibrosisBronchi
Quantitative assessment of airway dimensions in young children with cystic fibrosis lung disease using chest computed tomography
Pediatr Pulmonol.
Kuo W, Soffers T, Andrinopoulou ER, Rosenow T, Ranganathan S, Turkovic L, Stick SM, Tiddens HAWM; AREST CF
doi: 10.1002/ppul.23787.
RECOMMENDED
Pulmonary Fibrosis
Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Kawala CR, Ma X, Sykes J, Stanojevic S, Coriati A, Stephenson AL
doi: 10.1016/j.jcf.2021.03.008
Pulmonary Fibrosis
Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
N Engl J Med.
Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS
doi: 10.1056/
RECOMMENDED
Pulmonary Fibrosis
Lung CT densitometry in idiopathic pulmonary fibrosis (IPF) for the prediction of natural course, severity and mortality
Chest.
Loeh B, Brylski LT, von der Beck D, Seeger W, Krauss E, Bonniaud P, Crestani B, Vancheri C, Wells AU, Markart P, Breithecker A, Guenther A
doi: 10.1016/j.chest.